LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on IVA stock, giving a Buy rating yesterday.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight Inventiva’s promising future. The completion of enrollment for the Phase III NATiV3 trial marks a significant milestone for the company, setting the stage for topline data expected in the second half of 2026. This data will be crucial for regulatory submissions, potentially paving the way for accelerated approval in both the US and EU markets.
Additionally, the structured financing and milestone payments are expected to support the company’s operations through the third quarter of next year, providing a stable financial outlook. The trial’s design, which includes a primary endpoint of MASH resolution and fibrosis improvement, minimizes placebo risk and enhances the likelihood of replicating the positive results from the Phase II trial. If successful, lanifibranor could become a leading oral therapy in the MASH landscape, further justifying the Buy rating.
In another report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $20.00 price target.